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Aspergillus fumigatus Pneumonia in Neutropenic
Patients Receiving Fluconazole for Infection Due to
Candida Species: Is Amphotericin B Combined with
Fluconazole the Appropriate Answer?
dence that fluconazole combined with amphotericin B is supe-
rior to monotherapy with amphotericin B or a combination of
amphotericin B plus flucytosine, we caution against the wide-
spread use of combined therapy with amphotericin B and flu-
conazole for candidiasis or aspergillosis.
Stephan Pahls and Andreas Schaffner
Department ofMedicine, Universitiitsspital,
Zurich, Switzerland
Figure 1. Strain SD-I of Candida albicans. grown overnight in Sabouraud
dextrose broth, was exposed at a density of 106 cells/mi. in minimal essen-
tial medium (MEM: Gibco Europe, Basel. Switzerland) to 0.25 mg/L (0) or
0.5 mg/L (..) of fluconazole. At indicated times (hours 0-5), fungal cells
were washed three times in MEM and serial dilutions were transferred to
casitone agar plates with or without amphotericin B(2.5 mg/L) for determina-
tion of the percentage of yeast cells inhibited by amphotericin B.To maintain
the effect of fluconazole during exposure to amphotericin B, all casitone
plates were supplemented with a subinhibitory concentration of fluconazole.
After 5 hours. <0.1 '!c, of the yeast cells remained susceptible to amphotericin
B. and exposure to fluconazole was stopped by washing the yeast cells in
prewarmed MEM (WASH) prior to further incubation in MEM without anti-
mycotics. While pretreatment with fluconazole for 2 hours was necessary to
induce full antagonism between fluconazole and amphotericin B,yeast cells
grown in MEM without antifungal agents fully regained their susceptibility to
amphotericin B within I hour after washing. Reduction in the number of
colonies by exposure to amphotericin B is the mean based on results with
duplicate tubes from one of two comparable experiments.
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SIR-Meis et al. [1) rightly remind us in their recent letter that
fluconazole is insufficient therapy for invasive aspergillosis; they
summarize the cases of four neutropenic patients who died of
invasive aspergillosis while receiving fluconazole therapy for in-
vasive candidiasis [I). However, the conclusion drawn from
these observations raises some doubt. The authors justifiably
state that fluconazole should not be used as empirical antifungal
therapy in patients with suspected pulmonary mycoses, since
most mycotic infections are caused by Aspergillus species [2-4],
and these fungi are relatively resistant to fluconazole [5). Conse-
quently, Meis and collaborators conclude that clinicians "con-
sider combining amphotericin B with fluconazole ab initio for
treating proven candidal infection in any severely immunosup-
pressed patients, since they are also most at risk from infection
with both molds and azole-resistan t yeasts."
This recommendation deviates from several recent authorita-
tive recommendations on the use of amphotericin B, with or
without flucytosine, as standard therapy for invasive candidiasis
and/or aspergillosis [6- I2). Furthermore, the possibility of an-
tagonism between fluconazole (as well as other azoles) and am-
photericin B raises concern. Azoles inhibit ergosterol synthesis
and thereby eliminate the target for the activity ofamphotericin
B [13, 14). This antagonism has been widely confirmed for Can-
dida species and aspergilli on the basis of data from in vitro
studies [13-16) as well as those from experimental infections
[16-19). Published data on the antifungal activity of flucona-
zole plus amphotericin B are admittedly scarce, yet it is not
surprising that such antagonism can be brought about without
difficulty (figure I). Therefore, in the absence of clinical evi-
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Reply
SIR-We are not alone in our concern about the risk for the
development of invasive aspergillosis in patients who are being
treated with fluconazole [I]. Kappe and colleagues [2] noted
four such cases and concur with our view that the drug should
not be given alone to manage persistent fever when the patient is
at high risk of developing aspergillosis. Nevertheless. Drs. Pahls
and Schaffner are quite correct in highlighting the potential for
antagonism between amphotericin B and the azoles, since this
antagonism was shown to occur when the lipophilic agent keto-
conazole was evaluated in a murine model of invasive aspergil-
losis [3]. However. the outcome ofexposing Candida albicans to
a combination of the polyene and either miconazole or ketoco-
nazole appears to be critically dependent on the experimental
conditions; short-term incubation results in antagonism,
whereas the opposite occurs after prolonged exposure [4].
Drs. Pahls and Schaffner report antagonism between ampho-
tericin Band fluconazole (at a dose of0.25-0.5 mg/L), yet Sche-
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ven and Scheven [5] failed to detect any interaction despite pro-
longed preincubation of yeasts with 10-20 times the amount of
drug as that found in human serum following administration of
a 400-mg dose. Moreover. there is no evidence to support antag-
onism between the drugs in patients who have been treated with
high doses of fluconazole [6] or in a leukopenic rabbit model of
invasive aspergillosis [7]. This does not necessarily mean that
Drs. Pahls and Schaffner are dealing with a laboratory curiosity;
rather. the application of laboratory findings to the patient and
vice versa is never straightforward and must be approached from
the widest context possible.
Jacques F. Meis, J. Peter Donnelly,
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